VBI VACCINES INC. (TSE:VBV) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
VBI Vaccines Inc. (the “Company”) intends to use a slide presentation, which is attached hereto as Exhibit 99.1, to accompany a previously announced conference call and webcast to be held on June 17, 2019, at 8:00 a.m. Eastern Time, providing top-line results from PROTECT study, a pivotal Phase 3 study of Sci-B-Vac®. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing.
Item 8.01 Other Events.
On June 16, 2019, the Company issued a press release announcing the conference call and webcast to be held on June 17, 2019, at 8:00 a.m. Eastern Time. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
On June 17, 2019, the Company issued a press release announcing positive top-line results from the PROTECT study. A copy of the press release is attached as Exhibit 99.3 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 99.1* | Slide Presentation of VBI Vaccines Inc., dated June 17, 2019 |
| 99.2 | Press Release dated June 16, 2019 |
| 99.3 | Press Release dated June 17, 2019 |
* Furnished herewith
VBI Vaccines Inc/BC Exhibit
…
To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).